Using advanced AI technology, users can visualize realistic weight loss transformations before starting a GLP-1 program
Rather than guessing which medication adjustment to try next, PlexusDx uses your unique peptide genetics to recommend a personalized path forward
As its demand increases, the need for Semaglutide manufacturers in India becomes critical
According to the data provided by the Synapse Database, As of August 26, 2024, there are 143 investigational drugs for the CB1 targets, including 133 indications, 120 R&D institutions involved, Nimacimab is a monoclonal antibody that targets the CB1 receptor and is being developed for therapeutic areas including Nervous System Diseases, Digestive System Disorders, Endocrinology and Metabolic Disease, and Urogenital Diseases